# Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)

> **NCT00034684** · PHASE1,PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 132 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Chronic
- Blast Crisis
- Leukemia, Lymphocytic

## Interventions

- **DRUG:** Farnesyl Protein Transferase Inhibitor

## Key facts

- **NCT ID:** NCT00034684
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2003-10
- **Final completion:** 2003-10
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2015-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034684, "Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00034684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*